Supplements for Kidney Health: What to Know

Dietary supplements are used by an estimated 60–70% of patients with chronic kidney disease (CKD) — yet kidney disease creates some of the most complex and consequential supplement safety concerns of any medical condition. Unlike healthy adults, CKD patients cannot rely on the kidneys to excrete excess nutrients, minerals, and herb-derived compounds that accumulate in the blood. A supplement that is benign or even beneficial in a healthy person can be dangerous — or outright toxic — in someone with significantly reduced kidney function. At the same time, certain specific nutritional deficiencies are extremely common in CKD (vitamin D, B vitamins lost through dialysis, iron) and require targeted supplementation under medical supervision. Navigating this landscape — knowing which supplements are safe, which are hazardous, which claims have evidence, and how to have a productive conversation with the care team — is an important part of managing kidney health. This article covers the major supplement safety issues in CKD, reviews specific supplements relevant to kidney patients, and provides practical guidance for evaluating supplement use and discussing it with the nephrology team. For patients who want to understand how specific nutrients — phosphorus, potassium, vitamin D — are managed in CKD, the companion articles on kidney disease and mineral balance and kidney disease and bone health provide the relevant clinical context.

Why Supplement Safety Is Different in Kidney Disease

The kidney’s role in excreting water-soluble compounds, regulating mineral levels, and activating certain vitamins means that CKD fundamentally changes the pharmacokinetics and safety profile of many supplements. Understanding why requires understanding what the kidneys normally do with vitamins, minerals, and bioactive compounds. Impaired excretion of water-soluble compounds: water-soluble vitamins (vitamin C, B vitamins) and minerals (potassium, magnesium, phosphorus) are normally excreted by the kidneys in proportion to dietary intake. In CKD, this excretion is impaired, creating a risk of accumulation. High-dose vitamin C supplementation (above 250–500 mg/day in CKD patients) can cause oxalate accumulation — vitamin C is metabolized to oxalate, and excess oxalate deposits in the kidney tubules and other tissues, causing oxalate nephropathy and potentially accelerating kidney function decline. Potassium-containing supplements (including potassium-based salt substitutes, many electrolyte powders and sports drinks, and some multivitamins) can cause dangerous hyperkalemia in CKD patients with impaired potassium excretion. Magnesium supplements can cause hypermagnesemia in advanced CKD. Herbal supplement accumulation and nephrotoxicity: many herbal and botanical supplements contain compounds with direct nephrotoxic potential that are normally excreted by healthy kidneys but accumulate in CKD, creating a cycle of compounding toxicity. The most dangerous category is plants containing aristolochic acid — a potent nephrotoxin found in many traditional Chinese, Taiwanese, and Eastern European herbal medicines — including Aristolochia species, some Asarum species, and products that may be contaminated with these herbs. Aristolochic acid nephropathy (also called Chinese herb nephropathy) has caused kidney failure in thousands of patients worldwide and is associated with urothelial (upper urinary tract) cancer. Other herbs with documented nephrotoxic potential include: licorice root (can cause severe hypokalemia and hypertension); thunder god vine (Tripterygium wilfordii, used in Chinese medicine); pennyroyal oil; certain Ayurvedic preparations containing heavy metals (lead, mercury, arsenic); and unpurified preparations of chromium picolinate at high doses. Vitamin D complexity in CKD: the kidneys are responsible for activating vitamin D (converting 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D, the active form). In CKD, this activation is impaired, meaning supplementation with standard native vitamin D (cholecalciferol, D3) addresses only the precursor — it cannot fully correct vitamin D deficiency if kidney activation is severely impaired. Active vitamin D analogues (calcitriol, paricalcitol) bypass this step and require a prescription and monitoring. Supplementing with very high doses of native vitamin D without laboratory monitoring can cause vitamin D toxicity (hypercalcemia, vascular calcification) in some CKD patients — particularly those who also take calcium-containing phosphate binders or calcitriol. Fat-soluble vitamin accumulation: vitamins A, E, and K are fat-soluble and accumulate in the body; they are not dialyzed effectively. Vitamin A toxicity is well-documented in CKD patients who take standard multivitamins containing high doses of vitamin A (retinol) — symptoms include bone pain, liver damage, and hypercalcemia. Most standard multivitamins are not recommended in CKD; renal-specific multivitamin formulas (such as Nephrocaps, Renaphro, or Dialyvite) are formulated to provide the correct water-soluble vitamins without the fat-soluble vitamin excess. The NIDDK patient information on supplements and kidney disease is at the NIDDK CKD nutrition and supplements page.

Supplements That Require Caution or Avoidance in CKD

A practical list of supplement categories that CKD patients should approach with particular caution helps translate general safety principles into specific decisions. Potassium-containing products: electrolyte supplements, sports recovery powders, some protein powders, electrolyte tablets marketed for hydration, and products containing potassium chloride (including many “no-salt” or “low-sodium” alternatives) can provide significant potassium loads that healthy kidneys excrete but impaired kidneys cannot. CKD patients with hyperkalemia risk (eGFR below 45, stage 3b+) should check the supplement facts panel of any product for potassium content before use. High-dose vitamin C: supplementation above 250 mg/day in CKD patients is generally discouraged by nephrologists due to oxalate accumulation risk. Dietary vitamin C from food sources (fruits and vegetables) at typical intake levels is much less problematic. Patients who juice large volumes of citrus or take high-dose vitamin C supplements “for immune support” should discuss this with their nephrologist. Creatine monohydrate: widely used as a performance supplement, creatine increases serum creatinine (because it is metabolized to creatinine) — this can falsely suggest worsening kidney function on lab tests in healthy athletes. In CKD patients, this effect is amplified and can interfere with eGFR interpretation. The actual nephrotoxicity of creatine supplementation in CKD is uncertain but creatine is generally discouraged in CKD stage 3+ until better safety data are available. Protein powders and amino acid supplements: high-protein supplementation via protein powders (whey, casein, plant-based protein concentrates) adds significant protein load. In non-dialysis CKD patients on protein-restricted diets (typically 0.6–0.8 g/kg/day), additional protein supplementation can worsen proteinuria, increase nitrogen load, and contribute to hyperphosphatemia. In dialysis patients who need more protein, supplementation may be appropriate — but specific kidney-compatible products (lower phosphorus, lower potassium) are preferred over standard sports nutrition protein powders. Herbal products with documented kidney harm: beyond aristolochic acid-containing herbs, patients should also avoid tong kat ali (Eurycoma longifolia) at high doses; certain Chinese proprietary medicines without clear ingredient disclosure; and any product that lists proprietary blends without disclosing individual ingredient amounts. NSAIDs in supplement form: willow bark extract contains salicin (metabolized to salicylate, related to aspirin) and is marketed as a “natural” alternative to NSAIDs for pain. Like pharmaceutical NSAIDs, willow bark can reduce kidney perfusion and worsen kidney function in CKD. The NKF supplement safety resource is at the NKF herbal supplements and kidney disease page.

Supplements Commonly Used or Recommended in CKD

While caution and avoidance are the dominant themes in CKD supplement safety, certain targeted supplements are used and sometimes recommended by nephrologists for specific deficiencies or evidence-based benefits in kidney disease. Renal multivitamins (dialysis patients): dialysis removes water-soluble vitamins — folate, thiamine (B1), riboflavin (B2), B6, B12, biotin, pantothenic acid, and vitamin C — from the blood with each session. Dialysis patients require supplementation of these vitamins to replace dialytic losses. Standard renal vitamins (Nephrocaps, Dialyvite, or equivalent) are formulated for this purpose and are distinct from standard multivitamins in that they: provide higher levels of B vitamins and folate; provide only a small, safe amount of vitamin C (60–100 mg); and omit or minimize fat-soluble vitamins (A, E, K) that accumulate in kidney disease. Non-dialysis CKD patients generally do not need the same level of B vitamin supplementation unless specific deficiencies are documented. Vitamin D (native and active): as discussed in the companion article on vitamin D and kidney disease, 25-hydroxyvitamin D (calcidiol) deficiency is common in CKD, and supplementation with cholecalciferol (D3) or ergocalciferol (D2) is indicated when levels are below 30 ng/mL. Supplementation should be guided by lab testing and monitored, not self-prescribed at high doses. Active vitamin D (calcitriol, paricalcitol) is prescription-only and used under nephrology supervision for secondary hyperparathyroidism management. Iron: iron deficiency is nearly universal in dialysis patients (from blood losses during hemodialysis, reduced dietary iron absorption, and use of ESAs that consume iron stores rapidly) and very common in non-dialysis CKD. Oral iron supplementation is first-line in non-dialysis CKD with iron deficiency; intravenous iron is often necessary in dialysis patients because oral iron is incompletely absorbed and often insufficient. The article on kidney disease and anemia covers iron supplementation in the context of CKD anemia management in detail. Omega-3 fatty acids (fish oil): several clinical trials have evaluated omega-3 fatty acid supplementation in CKD, with findings suggesting modest reduction in proteinuria and possible blood pressure benefits. The KDIGO 2024 CKD guidelines include a discussion of omega-3 supplementation based on emerging cardiovascular outcome data. Omega-3s are generally safe in CKD at standard doses (2–4 g/day of combined EPA+DHA); they do not contain potassium or phosphorus, and there is no accumulation concern. However, they have antiplatelet effects that should be considered in patients who are also on blood thinners. Sodium bicarbonate: oral sodium bicarbonate supplementation is used under nephrology supervision to treat metabolic acidosis in CKD, as discussed in the mineral balance companion article. It is a medication, not a supplement, but is widely available over the counter and used by some patients. Doses should be guided by blood bicarbonate levels and nephrologist recommendation. Probiotics: an emerging area of supplement research in CKD focuses on using probiotics to modify the gut microbiome to reduce uremic toxin production — addressed in the companion article on probiotics and urinary health. The StatPearls reference on CKD nutrition and supplementation is at the StatPearls CKD resource.

How to Evaluate Supplement Claims and Talk to Your Nephrologist

The supplement industry is largely unregulated in the United States — supplements are not required to prove safety or efficacy before going to market, and claims such as “supports kidney health” or “cleanses the kidneys” are marketing language, not medical claims with regulatory backing. Helping CKD patients navigate this landscape requires critical evaluation skills and a productive approach to discussing supplements with their care team. Evaluating supplement quality and safety: look for third-party quality certification marks: NSF International, USP (United States Pharmacopeia), ConsumerLab, or Informed Sport certification indicate that the product has been independently tested to contain what it claims and not to contain prohibited contaminants. These certifications do not guarantee safety in CKD specifically, but they verify product quality and identity. Avoid products with long lists of undisclosed “proprietary blend” ingredients — if the individual ingredient amounts are not disclosed, the product cannot be properly safety-evaluated. Check for potassium and phosphorus on the supplement facts panel — amounts per serving should be noted and added to dietary intake estimates. Beware kidney-specific marketing: products marketed as “kidney cleanse,” “kidney flush,” “kidney detox,” or “kidney support” supplements have no regulatory support for these claims and have not been evaluated for safety in actual CKD patients. Some of these products contain diuretic herbs (dandelion, horsetail, buchu), herbal compounds with uncertain safety in impaired kidneys, or unlisted ingredients. CKD patients should be especially skeptical of products that specifically target “kidney health” as a marketing claim, because these products are developed for the general wellness market — not for people with actual kidney disease, for whom many standard herbal ingredients are potentially harmful. Telling your care team about all supplements: disclosure of all supplement use to the nephrologist and pharmacist is essential — not optional. Studies consistently show that CKD patients who take supplements often do not disclose them to their care teams, either because they consider them food-like or natural and therefore not “medications,” or because they fear judgment. In reality, nephrologists and renal pharmacists want to know about supplement use specifically because they understand the kidney-specific safety issues. The approach that works best is to bring all supplement bottles to the appointment, or to prepare a written list of every product with the dose and frequency. Practical questions to ask: before starting any supplement, CKD patients should be able to answer: Does this supplement contain potassium, phosphorus, or magnesium that could raise my levels? Has this supplement been tested in people with kidney disease at my eGFR level? Does this interact with any of my current medications? Is there an evidence-based reason I need this supplement, or am I taking it based on general wellness claims? Would a kidney-specific version of this product be more appropriate? Working through these questions with a nephrologist or renal pharmacist takes minutes but can prevent months of harm from an inappropriate supplement. The article on kidney disease and long-term monitoring covers the full spectrum of what to discuss with the care team at each stage of CKD, including medication and supplement review as part of routine care. The KDIGO CKD guidelines are at the KDIGO CKD evaluation guidelines page.

Sources: NIDDK CKD Nutrition · KDIGO CKD Guidelines · National Kidney Foundation · StatPearls: CKD